Luye Pharma Conbercept

(Conbercept)

ApprovedProtein / enzyme

Conbercept is used to treat wet age-related macular degeneration, a disease that causes vision loss in older adults, and diabetic macular edema, which is swelling in the back of the eye caused by diabetes.[2] Luye Pharma Conbercept is currently approved and in use across 13 indications[4].[1]

Luye Pharma Conbercept is one of 183 biologic programs targeting Choroidal Neovascularization. It is currently in Approved.

Indications

Total Trials

Active Trials

182

Competitors

Pipeline

Status by Indication[4][1]

Indication

Choroidal NeovascularizationActive, not recruiting

Proliferative Diabetic RetinopathyActive, not recruiting

Corneal NeovascularizationActive, not recruiting

Wet Macular DegenerationActive, not recruiting

Retinopathy of PrematurityActive, not recruiting

RetinoblastomaActive, not recruiting

Retinal Vein OcclusionActive, not recruiting

Polypoidal Choroidal VasculopathyActive, not recruiting

Wet Age-Related Macular DegenerationActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Choroidal NeovascularizationPhase 2

Active, not recruiting

Proliferative Diabetic RetinopathyPhase 2

Active, not recruiting

Corneal NeovascularizationPhase 1

Active, not recruiting

Wet Macular DegenerationPhase 2

Active, not recruiting

Retinopathy of PrematurityPreclinical

Active, not recruiting

RetinoblastomaPhase 2

Active, not recruiting

Retinal Vein OcclusionPhase 2

Active, not recruiting

Polypoidal Choroidal VasculopathyPreclinical

Active, not recruiting

Diabetic Macular EdemaPhase 3

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Approved

1 6

Macugen

Pfizer

Phase 3

6 7

Avastin

BBio-Thera Solutions

Phase 3

18 8

Retaane

AAlcon Research

Phase 3

5 9

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 10

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Retinopathy of Prematurity

NCT06717412

Clinical

Trials by Indication[1]

Diabetic Macular Edema3 trials

Evaluation of RC28-E Injection in Diabetic Macular Edema

Completed·RRemeGen Co., Ltd.·Phase 2·NCT04782115·156 enrolled

Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 3·NCT02194634·248 enrolled

Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)

Unknown status·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT04627402·50 enrolled

Retinal Vein Occlusion3 trials

Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion

Completed·CChengdu Kanghong Biotech Co., Ltd.·Phase 3·NCT03108352·255 enrolled

Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion

Completed·CChengdu Kanghong Biotech Co., Ltd.·Phase 3·NCT03223714·242 enrolled

Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 2·NCT01809236·60 enrolled

Polypoidal choroidal vasculopathy2 trials

Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

Completed·PPeking Union Medical College Hospital··NCT05229237·500 enrolled

The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 4·NCT03159884·300 enrolled

Treatment2 trials

Head to Head Study of Anti-VEGF Treatment.

Completed· Novartis logo

Novartis·Phase 4·NCT02577107·12 enrolled

Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma

Unknown status·SSun Yat-sen University·Phase 1·NCT03973125·50 enrolled

Choroidal Neovascularization2 trials

Intravitreal Conbercept for Idiopathic Choroidal Neovascularization

Unknown status·JJiao Mingfei·Phase 2·NCT02857517·50 enrolled

Conbercept in Choroidal Neovascularization Secondary to Uveitis

Unknown status·—·Phase 2·NCT02934841·40 enrolled

11 more indications

Wet Age-Related Macular Degeneration1 trial

An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 2·NCT02098720·30 enrolled

Retinopathy of Prematurity1 trial

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

Recruiting·WWang Yusheng·N/A·NCT06717412·146 enrolled

Non-Proliferative Diabetic Retinopathy1 trial

Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy

Active, not recruiting·SShanghai Eye Disease Prevention and Treatment Center·Phase 4·NCT06305143·58 enrolled

TIA1 trial

Initial Versus Delayed PDT Combination With Conbercept in PCV

Completed·—·Phase 4·NCT02821520·80 enrolled

Retinoblastoma1 trial

A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 2·NCT04990271·92 enrolled

Effectiveness1 trial

Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma

Unknown status·SSun Yat-sen University·Phase 1·NCT03571282·50 enrolled

Proliferative Diabetic Retinopathy1 trial

Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy

Completed·RRuijin Hospital·Phase 4·NCT02816710·112 enrolled

PRP1 trial

PRP vs PRP+IVC for Severe nPDR

Unknown status·RRuijin Hospital·N/A·NCT03863535·40 enrolled

Age-Related Macular Degeneration1 trial

Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration

Unknown status·XXiaodong Sun·Phase 4·NCT02802657·141 enrolled

Vitrectomy1 trial

Intravitreal Conbercept After Vitrectomy

Completed·TTianjin Medical University Eye Hospital·Phase 1·NCT03426540·50 enrolled

Unspecified1 trial

Anti-VEGF in Real-world

Unknown status·WWenbin Wei··NCT05222633·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Conbercept. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Luye Pharma Conbercept drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Conbercept compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Conbercept. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Chengdu Kanghong Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vascular Endothelial Growth Factor B Inhibitor; Vascular Endothelial Growth Factor C Inhibitor; Placenta Growth Factor Inhibitor; Vascular Endothelial Growth Factor a Inhibitor[3]
Modality: Protein / enzyme[3]
Highest Phase: Approved[1]
Company: CChengdu Kanghong Biotech Co., Ltd.

Luye Pharma Conbercept

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Diabetic Macular Edema3 trials

Retinal Vein Occlusion3 trials

Polypoidal choroidal vasculopathy2 trials

Treatment2 trials

Choroidal Neovascularization2 trials

Wet Age-Related Macular Degeneration1 trial

Retinopathy of Prematurity1 trial

Non-Proliferative Diabetic Retinopathy1 trial

TIA1 trial

Retinoblastoma1 trial

Effectiveness1 trial

Proliferative Diabetic Retinopathy1 trial

PRP1 trial

Age-Related Macular Degeneration1 trial

Vitrectomy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News